Fate Therapeutics
FATE
FATE
130 hedge funds and large institutions have $76.2M invested in Fate Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
130
Holders Change
-27
Holders Change %
-17.2%
% of All Funds
1.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
40
Reduced
40
Closed
42
Calls
$64K
Puts
$6K
Net Calls
+$58K
Net Calls Change
+$6K
Top Buyers
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.16M |
| 2 |
JPMorgan Chase & Co
New York
|
+$1.37M |
| 3 |
Citigroup
New York
|
+$913K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$789K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$649K |
Top Sellers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$7.99M |
| 2 |
DM
Deerfield Management
New York
|
-$5.87M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.03M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$2.28M |
| 5 |
D.E. Shaw & Co
New York
|
-$872K |
